id: marketplace_plan_availability_to_sud_treatment_facility_density
name: Marketplace Plan Availability â†’ SUD Treatment Facility Density
from_node:
  node_id: marketplace_plan_availability
  node_name: Marketplace Plan Availability
  _original_id: mat_pharmacotherapy_availability
to_node:
  node_id: sud_treatment_facility_density
  node_name: SUD Treatment Facility Density
  _original_id: oud_treatment_effectiveness
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Three FDA-approved medications (methadone, buprenorphine, naltrexone) provide
  proven effective pharmacological treatment for OUD'
- 'Step 2: MAT medications address neurobiological mechanisms of opioid dependence
  through agonist, partial agonist, or antagonist actions'
- 'Step 3: Access to evidence-based pharmacotherapy reduces withdrawal symptoms, cravings,
  and risk of overdose'
- 'Step 4: Increased availability and accessibility of MAT medications improves treatment
  outcomes and reduces opioid-related morbidity and mortality'
evidence:
  quality_rating: A
  n_studies: 5
  primary_citation: Nessreen Ghanem et al. 2022. "Review of medication-assisted treatment
    for opioid use disorder." *Journal of Osteopathic Medicine*. https://doi.org/10.1515/jom-2021-0163
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.648197'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: comprehensive_treatment_integration
  direction: strengthens
  strength: moderate
  description: MAT effectiveness is enhanced when integrated with comprehensive treatment
    approaches including behavioral health services
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/mat_pharmacotherapy_availability_to_oud_treatment_effectiveness.yaml
_category: healthcare_access
